Iruxol Mono (Collagenase Clostridium Histolyticum, Protease)

The active enzyme, Collagenase Clostridium Histolyticum, selectively cleaves collagen and other extracellular matrix proteins that compose necrotic tissue. This enzymatic breakdown loosens and dissolves devitalized tissue while sparing viable cells, allowing the body’s natural healing mechanisms to take over and promote wound repair.

The dose and frequency of Iruxol Mono are determined by the prescribing clinician based on wound size, depth, and patient condition. Healthcare professionals apply the product according to their assessment and local clinical guidelines; patients should follow the prescriber’s instructions exactly.

Safety data for Iruxol Mono in pregnancy or lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Iruxol Mono, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iruxol Mono offers enzymatic debridement, which is selective for necrotic tissue and generally less painful than mechanical or surgical methods. Compared with chemical agents such as autolytic dressings, it works more rapidly, while avoiding the non‑specific tissue damage sometimes seen with sharp debridement. Choice of agent depends on wound characteristics and clinician preference.

Iruxol Mono should be stored at 2‑8 °C, kept refrigerated in its original packaging, protected from light, and must not be frozen or shaken. Before use, allow the product to reach room temperature if required, and handle with clean gloves to maintain sterility.

The prescriber directs the application method, which typically involves cleaning the wound, applying a thin layer of the enzyme directly to the necrotic area, and covering with an appropriate dressing. The dressing is usually changed according to the clinician’s schedule, allowing the enzyme to act on the tissue between changes.

Serious risks include severe allergic reactions such as anaphylaxis, secondary wound infection, and systemic hypersensitivity that may present with fever or rash. Patients should be monitored for rapid swelling, difficulty breathing, or signs of infection, and medical attention should be sought immediately if these occur.

Iruxol Mono should not be used in individuals with a known hypersensitivity to collagenase, protease enzymes, or any excipients in the formulation. It is also contraindicated on healthy, intact skin, and should be avoided in patients where necrotic tissue is absent or when alternative debridement methods are more appropriate.